Is COVID-19 the long overdue wake-up call for pharma supply chains?
GMP Review
; 19(2):4-7, 2020.
Article
in English
| Scopus | ID: covidwho-964226
ABSTRACT
This paper describes how the exclusive focus on non-clinical and clinical data collection during the development of medicines and healthcare products results in supply chains that are riddled with risk and issues. In the main, this is due to little awareness among actors in the development process of the seminal impact decisions taken here can have on the quality, cost and lead-time performance of the future commercial supply chain. In the author’s experience, things will only begin to improve if product developers open their minds to a totally new model for product development – one that begins with its end-users – patients and healthcare professionals. The paper concludes with a call for strategic supply chain management being exercised from the inception of a development programme. © 2020, Euromed Communications. All rights reserved.
Search on Google
Collection:
Databases of international organizations
Database:
Scopus
Topics:
Long Covid
Language:
English
Journal:
GMP Review
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS